Efficacy evaluation of Weiwei decotion in the treatment of chronic atrophic gastritis based on endoscope

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR1900002860

Enrollment

Unknown

Registered

2019-12-21

Start date

2019-12-20

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Atrophic Gastritis

Interventions

Experimental group:Routine treatment + Weiwe decoction treatment

Control group:Routine treatment

Eligibility

Sex/Gender

Male

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) meet the diagnostic criteria of CAG; (2) Aged between 18 and 65 years old; (3) signed informed consent, and completed treatment and follow-up as required;

Exclusion criteria

Exclusion criteria: (1) PPI and/or non-steroidal anti-inflammatory drugs (nsaids), antiplatelet drugs and anticoagulants, and mucosal protectants were used within the previous month; (2) a history of gastric ulcer, gastric cancer and gastric surgery; (3) having heart, lung, liver, kidney, blood system or life-threatening diseases (such as cancer and AIDS); (4) mental disorder or a history of alcoholism or drug abuse; (5) female patients undergoing labor, pregnancy or lactation; (6) participating or participating in another drug trial within the last three months.

Design outcomes

Primary

Measure	Time frame
Endoscopic diagnosis;Gastric mucosa transcriptome changes;Pathology classification;	—

Countries

China

Contacts

Public ContactBin Huang

1677825889@qq.com+86 13808838218

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026